✅ No sanctions, screening, insolvency or control red flags found in the public sources we cover. (Absence of a flag is not a guarantee — see methodology.)
L'OREAL
SA à directoire · Active since 1963
Overview
L'OREAL is a SA à directoire registered in paris, France, since 1963. Its TraceComp score of 80 (A) indicates solid fundamentals and low apparent risk. With 63 years of operations, the company has an established track record in its market.
Company Information
- Registration Number
- 632012100
- Legal Form
- SA à directoire
- Registered
- 1963-01-01
- Address
- Paris
Officers & Management
20 officers/directors on file — names, roles, appointment & resignation dates.
| Name | Role | Status |
|---|---|---|
| JEAN-PAUL AGON | Président du conseil d'administration | Current |
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Public Contracts Won
Awarded 1 public-sector contract totalling EUR 20,000 (DECP).
Which public buyers, contract titles, values and award dates.
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Research Output
Active research organization. 2,787 publications · 234,878 citations · h-index 186 in the global scholarly record (OpenAlex — 82.9M papers). Top fields by publication volume: Medicine (64%) · Pharmacology, Toxicology and Pharmaceutics (11%) · Veterinary (10%).
See full research profile — top researchers & publications →
Source: OpenAlex (CC0). Objective publication & citation counts.
EU Funding
EU-funded innovation. Participated in 6 EU research projects, receiving €34,540 in EU contributions (CORDIS — Horizon Europe / Horizon 2020).
Source: CORDIS (EU Open Data, CC-BY). Cumulative EC contribution across the company’s projects.
Patent Portfolio
Active patent holder. 4,992 patents · 2,368 active · 4,992 granted in the USPTO/EPO record.
See full patent portfolio — most-cited inventions & inventors →
Source: USPTO / EPO open patent data. Objective bibliographic counts.
Risk Signals
No adverse legal events have been recorded for this company.
- No financial filings on record — score derives from registry signals and sector context
Similar Companies
Data Sources & Freshness
Data sourced from: official public registries.